Amoeba SA · EURONEXT:ALMIB

Amoeba SA — Non-Deal Roadshow (October 2022)

28 slides from Amoeba SA's roadshow presentation, October 2022

  1. Slide 1: Roadshow Presentation 2022

    Slide 1: Roadshow Presentation 2022

    tena) hate a avioéba ns ROADSHOW PRESENTATION 2022 |

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER When receiving this presentation or participating in this meeting, you acknowledge having taken note of the following restrictions. The present document and the information contained in the presentation are strictly confidential. This document cannot be copied, reproduced, distributed, pu

  3. Slide 3: Amoeba's Market Valuation

    Slide 3: Amoeba's Market Valuation

    AMOEBA’S MARKET VALUATION CAP 2022 Submission of Market Cap R&D stage an AMM dossier Commercialization 200 M€ Agrauxine * 100% / € 45M Biotalys * 0% / Outsourcing 100 M € Antofénol Amoéba * 13% / € 53 M * 13% / € 17 M 50 M € Maturity * Functional plant / investment

  4. Slide 4: Amoeba's TAM Positioning

    Slide 4: Amoeba's TAM Positioning

    TAM 12 MDSPOSITIONING AMOEBA’S EUROS Rice Strawberry Env. € 1000 M In the testing process Vines Vegetables Potato Arboricultures € 800M € 600M € 250M Banana and others (powdery and mildew ) Env. € 500 M Env. € 100 M Wheat Soybeans € 2 400M € 2 100M Global Market potential : € 7 750 Mds

  5. Slide 5: Biocide, a Valuable Asset of Amoeba

    Slide 5: Biocide, a Valuable Asset of Amoeba

    BIOCIDE, A VALUABLE ASSET OF AMOEBA The first biological biocide for industrial water treatment • A patented innovation in a sector that has been stagnant for 50 years • Favorable pre-decision in the USA for use in closed cooling systems (definitive at the end of 2022) $ 10 M Of construction costs f

  6. Slide 6: 2024 Forecast

    Slide 6: 2024 Forecast

    2024 FORECAST To guarantee the emergence of a future French world leader in biocontrol Contribute to the creation of a biocontrol industrial network in France Thanks to our solid pillars Scientific maturity • 10 years of R&D • 9 scientific publications Regulatory maturity • Europe: Recommendation fo

  7. Slide 7: Towards a New Request to the Market

    Slide 7: Towards a New Request to the Market

    TOWARDS A NEW REQUEST TO THE MARKET « Since the creation of Amoéba, our funding has allowed us to reach a level of maturity on our 3 pillars: scientific, industrial and regulatory. Our objectives have been reached, notably by the completion of numerous field trials, the positive recommendation of Au

  8. Slide 8: Amoeba Presentation

    Slide 8: Amoeba Presentation

    1 AMOEBA PRESENTATION co amoeba

  9. Slide 9: About Amoeba

    Slide 9: About Amoeba

    ABOUT AMOEBA Amoéba is a Lyon-based biotech company specialized in the treatment of microbiological risk for natural resources. 1 microorganism, 2 applications Live amoeba BIOCIDE Dedicated to industrial water treatment Lysate of amoeba BIOCONTROL PRODUCT Dedicated to crop protection

  10. Slide 10: Our Vision and Mission

    Slide 10: Our Vision and Mission

    OUR VISION AND MISSION Ensuring a sustainable Develop a scientific and future by offering biological industrial expertise to alternatives that respect contribute to expand the human health and the offer of eco-friendly environment products Demonstrate our relevance Leading the way for other and posi

  11. Slide 11: Amoeba Key Figures

    Slide 11: Amoeba Key Figures

    AMOEBA KEY FIGURES 25 Millions of euros invested in R&D since 2010 26 Employees in France 1 Industrial center dedicated to our production

  12. Slide 12: Board of Directors

    Slide 12: Board of Directors

    COMITE DEDIRECTORS BOARD OF DIRECTION Fabrice Plasson Valérie Filiatre Bernard Ambolet CEO Administrator & Administrator Expert in life science and Chief Financial Officer Expert in agriculture and biotechnologies Expert in business administration Biocontrol and finance Pierre Morgon Sylvie Guinard

  13. Slide 13: Comité de Direction

    Slide 13: Comité de Direction

    COMITE DE DIRECTION Fabrice Plasson Valérie Filiatre Jean-Luc Souche CEO Administrator & Business Developer Biocontrol Expert in life science and Chief Financial Officer Specialist in plant protection biotechnologies Expert in business administration and finance Sandrine Troussieux Jean-Baptiste Ebe

  14. Slide 14: Financial Informations

    Slide 14: Financial Informations

    2 - FINANCIAL INFORMATIONS ha al

  15. Slide 15: Financing and Shareholding

    Slide 15: Financing and Shareholding

    FINANCING AND SHAREHOLDING Distribution of € 13.2 M Raised during the IPO in July 2015 shareholding € 14.7 M Raised in 2016 by private placement 5% Financing agreement with the European €5M Investment Bank (EIB) in 2017 € 15,8 M OCAPI with Nice & Green between 2018 and 2021 95% €6M Other funds raise

  16. Slide 16: Financial Situation

    Slide 16: Financial Situation

    FINANCIAL SITUATION SITUATION FINANCIERE BURN RATE EIB DEBT Refunded in June 2022 2020 2021 2020 2021 € 410 K € 370 K € 7,9 M € 6,1 M EQUITY CASHFLOW 2020 2021 2020 2021 € 2,0 M € 0,2 M €5M € 7,3 M

  17. Slide 17: Biocontrol

    Slide 17: Biocontrol

    ' BIOCONTROL he ' py f

  18. Slide 18: État de l'art – Biocontrol Context

    Slide 18: État de l'art – Biocontrol Context

    ETAT DE L’ART – BIOCONTROLE CONTEXT EUROPEAN OBJECTIVE Limited biocontrol High solutions To find "green" alternative but environmental Ancient pesticides equally effective solutions. impact increasingly banned 78% reduction of (EU), including copper insects between submitted for re- 1989 and 2013 ev

  19. Slide 19: Our Solution

    Slide 19: Our Solution

    OUR SOLUTION A 100% natural biofungicide Effectiveness in 50-80% fields In-field trials by 300 Amoéba since 2019 180 In-field trials by partners since 2019

  20. Slide 20: Value Proposition

    Slide 20: Value Proposition

    VALUE PROPOSITION Facilitating the transition from conventional to organic agriculture Conventional Organic Substitutes market market Thanks to our solution : • A unique dual mode of action (elicitor and fungicide) • A wide spectrum of activity (vineyards, vegetables, potatoes, cereals...) • A good

  21. Slide 21: Key Factors of Success

    Slide 21: Key Factors of Success

    KEY FACTORS OF SUCCESS An innovative and unique product An active substance recommended from a class of microorganisms never for approval by the Rapporteur used before in agriculture: amoebas Member State (Austria) A product with no hazard class A product with no residue limit and a low risk profile

  22. Slide 22: Industrialization

    Slide 22: Industrialization

    4 INDUSTRIALIZATION

  23. Slide 23: Industrialization

    Slide 23: Industrialization

    INDUSTRIALIZATION Chassieu Industrial R&D Center 2 x 500 L Production capacity of bioreactors 500 KG of active substance produced per year

  24. Slide 24: Production Site Expansion Project

    Slide 24: Production Site Expansion Project

    PRODUCTION SITE EXPANSION PROJECT Creation of a new duplicable factory Biocontrol production line 30 T of additional active substance Capacity 20x higher than Chassieu € 17 M of investments A certified site "Label Parc+". • Preservation and valuation of the environment • 80% of roofs covered with ph

  25. Slide 25: Optimization of Industrial Performance

    Slide 25: Optimization of Industrial Performance

    OPTIMIZATION OF INDUSTRIAL PERFORMANCE 2022 2023 2024 APS APD PC Instruction Construction site Qualif. Go Live INDUSTRIAL PROJECT NOE (existing test line) Pilot line (Chassieu) USIBIAM (Vaucluse) Bioreactor : 1 x 3000 L Bioreactors : 4 x 5000 L Bioreactors : 2 x 500 L Implementation of a pilot A.I.

  26. Slide 26: Amoeba's TAM Strategy 2024-2026

    Slide 26: Amoeba's TAM Strategy 2024-2026

    AMOEBA’S TAM 12 MDSSTRATEGY EUROS 2024-2026 A volume and profitability strategy 40 tons of AS/year = 100 000 hectares treated Vines Lettuce Tomato Aromatic herbs (2 771 000 hectares) (500 000 hectares) (280 000 hectares) (30 000 hectares) Price/ Price/ Price/ Price/ ha ha ha ha 50 € 80 € 80 € 200 €

  27. Slide 27: Amoeba's Project Financing

    Slide 27: Amoeba's Project Financing

    AMOEBA’S PROJECT FINANCING FUNDING € 5,9 M € 32 M Maximum funding « France 2030 » (35%) required for the realization of the project € 3,2 M Current bond issue € 17 M €5M Dedicated to the factory construction Bank loan € 15 M € 18 M Dedicated to operating expenses over Capital increase 2023 - 2024

  28. Slide 28: Social Media, Website, Contact

    Slide 28: Social Media, Website, Contact

    Social Media Website Contact @AmoebaNature amoeba-nature.com contact@amoeba-nature.com ROADSHOW PRESENTATION 2022

Source: Internet Archive copy of amoeba-nature.com

More decks from Amoeba SA

All 22 Amoeba SA decks